Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

SML0050

Sigma-Aldrich

CGP 37849

≥98% (HPLC)

Synonym(s):

(3E)-2-Amino-4-methyl-5-phosphono-3-pentanoic acid

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C6H12NO5P
CAS Number:
127910-31-0
Molecular Weight:
209.14
MDL number:
MFCD00153906
UNSPSC Code:
12352200
PubChem Substance ID:
329825119
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: ≥2 mg/mL (warmed)

storage temp.

2-8°C

SMILES string

C\C(CP(O)(O)=O)=C/C(N)C(O)=O

InChI

1S/C6H12NO5P/c1-4(3-13(10,11)12)2-5(7)6(8)9/h2,5H,3,7H2,1H3,(H,8,9)(H2,10,11,12)/b4-2+

InChI key

BDYHNCZIGYIOGJ-DUXPYHPUSA-N

Application

CGP 37849 may be used in NMDA-mediated cell signaling studies.

Biochem/physiol Actions

CGP 37849 induces phencyclidine-like behavioral syndrome in amygdala-kindled rats that includes ataxia, locomotion and stereotypies.
CGP 37849 is a potent orally active competitive NMDA antagonist and anticonvulsant.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

W Löscher et al.
The Journal of pharmacology and experimental therapeutics, 257(3), 1146-1153 (1991-06-01)
The novel competitive N-methyl-D-aspartate (NMDA) receptor antagonist DL-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid (CGP 37849) was found to produce a phencyclidine (PCP)-like behavioral syndrome (ataxia, locomotion, stereotypies) in amygdala-kindled rats, whereas the amphetamine-like behavioral alterations of the syndrome (locomotion, stereotypies) were only infrequently seen
Romana Slamberová et al.
European journal of pharmacology, 516(1), 10-17 (2005-05-21)
Epileptic afterdischarges elicited by stimulation of sensorimotor cortex were chosen to test anticonvulsant effects of NMDA receptor antagonists in developing rats (12, 18 and 25 days old) with implanted electrodes. Afterdischarges were elicited four times with 10-min intervals in the
Krzysztof Wedzony et al.
Brain research, 1062(1-2), 166-170 (2005-11-01)
The present study assessed whether the blockade of NMDA receptors in the postnatal period, used to model the symptoms of schizophrenia altered morphology of pyramidal neurons in the medial prefrontal cortex of rats. CGP 40116, an antagonist of NMDA receptors
Giacinto Bagetta et al.
Basic & clinical pharmacology & toxicology, 94(3), 132-138 (2004-04-01)
The epileptogenic and neurodegenerative effects of gamma-dendrotoxin, from Dendroaspis angusticeps, a specific blocker of a non-inactivating, voltage-sensitive K+ channel, were studied after focal injection into one dorsal hippocampus in rats pretreated with CGP040116, a N-methyl-D-aspartate (NMDA) receptor antagonist, and in
Janel M Boyce-Rustay et al.
Synapse (New York, N.Y.), 56(4), 222-225 (2005-04-02)
The present study examined the roles of NR2A and NR2B subunit-containing NMDA receptors in the mediation of the sedative/hypnotic effects of ethanol in mice. The ability of the competitive NMDA antagonist, CGP-37849 (0, 1, or 3 mg/kg), and the NR2B-selective
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service